Chardan Capital Reiterates “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Chardan Capital reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report released on Thursday morning,Benzinga reports. They currently have a $7.00 target price on the stock.

TSHA has been the subject of a number of other reports. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group decreased their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Finally, Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Trading Down 9.3 %

Shares of TSHA opened at $2.06 on Thursday. Taysha Gene Therapies has a fifty-two week low of $1.19 and a fifty-two week high of $4.32. The stock has a fifty day moving average of $1.98 and a two-hundred day moving average of $2.38. The company has a market capitalization of $422.18 million, a PE ratio of 3.27 and a beta of 0.44. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.22 and a current ratio of 5.51.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning bought a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at about $28,000. China Universal Asset Management Co. Ltd. raised its position in shares of Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after acquiring an additional 17,446 shares during the period. Privium Fund Management B.V. boosted its stake in Taysha Gene Therapies by 21.8% during the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock worth $241,000 after acquiring an additional 21,500 shares during the last quarter. Principal Financial Group Inc. bought a new stake in Taysha Gene Therapies in the second quarter valued at approximately $48,000. Finally, Artal Group S.A. boosted its position in shares of Taysha Gene Therapies by 0.7% during the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after purchasing an additional 24,444 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.